Author:
Sehouli Jalid, ,Camara O.,Schmidt M.,Mahner S.,Seipelt G.,Otremba B.,Schmalfeldt B.,Tesch H.,Lorenz-Schlüter C.,Oskay-Özcelik G.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference16 articles.
1. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C (2003) ICON ans AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR 2.2 trial. Lancet 361(9375):2099–2106
2. McGuire WP (2001) Primary therapy of epithelial ovarian cancer. In: Perry MC (Ed) American society of clinical oncology educational book, pp 477–480
3. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E (2006) The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 94:1615–1620
4. Vermorken JB (2003) The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer 13:178–184
5. Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin North Am 8:431–450
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献